Clinical trial · Interventional
Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization
Open Label Phase II Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Poor mobilization of hematopoietic progenitors needed to support autologous transplantation is a serious clinical problem. We are investigating the role of plerixafor administered in an at risk population to augment successful stem cell collection. OBJECTIVES To determine if plerixafor when administered on the day prior to planned autologous collection on first mobilization attempt in those with a peripheral blood CD34 ≤ 10X106/L will: * increase the number of patients successfully collected in one day * increase the number of patients successfully mobilized on first collection attempt * is cost neutral within a Canadian setting
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Observation: Nonintervention | Other | — | UNRESOLVED |
| Plerixafor | Drug | Plerixafor | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Successful Mobilizers
- description
- Successful Mobilizers are defined as having a peripheral blood CD34 \> 10X106/L.
- interventionNames
- Other: Observation: Nonintervention
- type
- EXPERIMENTAL
- label
- Poor Mobilizers
- description
- Poor Mobilizer are defined as patients who on Day -1 have a peripheral blood \[CD34\] ≤ 10 X106/L
- interventionNames
- Drug: Plerixafor
Primary outcomes (1)
- measure
- To increase the proportion of Poor Mobilizers who after receiving plerixafor are successfully collected in one day. The anticipated proportion increase is from 30%-60%.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Participants must be 18 years of age or older 2. Patients must be able to provide written consent 3. Participants must have a diagnosis of lymphoma or multiple myeloma and be undergoing autologous stem cell mobilization for the purposes of ASCT 4. Females of child bearing age will be asked to use an approved form of contraception Exclusion Criteria: 1. Patients who are pregnant or breastfeeding 2. Patients whose creatinine ≥ 250 μM 3. Serum AST, ALT or total bilirubin \>5X upper limit of normal 4. Acute infection
References
Publications (0)
Data not yet available